01
Commercial
Personalized Cancer Vaccines Market to Reach US$ 30.12 Billion - openPR.com
A DataM Intelligence press release forecasts the personalized cancer vaccines market reaching US$30.12 billion by 2033 at an 11.5% CAGR, naming Gritstone Bio, CureVac, and Transgene as key players. Treat the figures as directional: this is vendor-published via openPR, not peer-reviewed, with no methodology disclosed. The signal worth noting is continued third-party framing of personalized immunotherapy as a growth market through the next decade.